Literature DB >> 17004021

The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.

Hein A van Onzenoort1, Michiel Bussink, Paul P Menheere, Walther N van Mook, Paul-Hugo M van der Kuy.   

Abstract

A 44-year-old woman, with a history of familial adenomatous polyposis, complicated by carcinoma of the colon, for which a proctocolectomy had been performed, now presented with metastasis located in the pancreas. Treatment consisted of chemotherapy followed by a partial pancreaticoduodenectomy. Due to ischemia, resection of the small intestines was performed the same day. After admission, a transesophageal echocardiography showed an ejection fraction of 40%. Because enteral administration of drugs was impossible, intravenous enalaprilat 2 mg once a day for 1 day followed by sublingual captopril 25 mg twice a day were started. Blood samples were taken before and after administration. After 1 day of sublingual captopril treatment the angiotensin II level decreased with more than 50%, comparable to the decrease seen after intravenous administration of enalaprilat. Sublingual captopril has been used in the treatment of hypertensive crisis and heart failure. Although frequently reported, no study has investigated the effect on angiotensin II levels after sublingual administration in heart failure patients. This case-report demonstrated that sublingual administration of 25 mg captopril twice a day yielded a considerable decrease in angiotensin II plasma levels which was comparable to the effect seen after an intravenous administration of 2 mg enalaprilat.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004021     DOI: 10.1007/s11096-006-9024-8

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  11 in total

1.  Evaluation of the effect of the sublingually administered nifedipine and captopril via transcranial doppler ultrasonography during hypertensive crisis.

Authors:  Kani Gemici; Ibrahim Baran; Mustafa Bakar; Celalettin Demircan; Bülent Ozdemir; Jale Cordan
Journal:  Blood Press       Date:  2003       Impact factor: 2.835

2.  Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation.

Authors:  T A al-Furaih; J C McElnay; J S Elborn; R Rusk; M G Scott; J McMahon; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Treatment of hypertensive crisis with sublingual captopril.

Authors:  G N Karachalios; A N Georgiopoulos
Journal:  Clin Pharm       Date:  1989-02

4.  The Effects of Sublingual Administration of Captopril on Parameters of Exercise Test and Neurohormonal Activation in Patients With Stable Angina Pectoris

Authors: 
Journal:  Int J Angiol       Date:  1998-05

5.  Dose-response effect of sublingual captopril in hypertensive crises.

Authors:  A Castro del Castillo; M Rodriguez; E Gonzalez; F Rodriguez; J Estruch
Journal:  J Clin Pharmacol       Date:  1988-07       Impact factor: 3.126

6.  Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure.

Authors:  M Haude; W Steffen; R Erbel; J Meyer
Journal:  Int J Cardiol       Date:  1990-06       Impact factor: 4.164

7.  Sublingual captopril in hypertensive crisis.

Authors:  W Tschollar; G G Belz
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

8.  A Comparison of Safety and Efficacy of Sublingual Captopril with Sublingual Nifedipine in Hypertensive Crisis.

Authors: 
Journal:  Int J Angiol       Date:  1999-06

9.  A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  ED management of acute congestive heart failure in renal dialysis patients.

Authors:  A Sacchetti; J McCabe; M Torres; R L Harris
Journal:  Am J Emerg Med       Date:  1993-11       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.